A Randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)

Oncologist

Volumn 17, Issue 7, 2012, Pages 937-946

  Hurwitz, Herbert ^a   Mitchell, Edith P ^b   Cartwright, Thomas ^c   Kwok, Ambrose ^d   Hu, Sylvia ^e   Mckenna, Edward ^e   Patt, Yehuda Z ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c US Oncology Research Inc   (United States)

^d Everest Clinical Research Services Inc   (Canada)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Bevacizumab; Capecitabine; Clinical trial; Metastatic colorectal cancer; Progression free survival; Toxicity; XELOX

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TEMPERATURE SENSITIVITY; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84864028215     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0071     Document Type: Article

References (18)

1. National Comprehensive Cancer Network. Colon Cancer. v. 2.2010. Available at http://www.nccn.org/ professionals/physician_gls/PDF/colon.pdf, accessed May 14, 2010.
2. National Comprehensive Cancer Network. Rectal Cancer. v. 2.2010. Available at http://www.nccn.org/ professionals/physician_gls/PDF/rectal.pdf, accessed May 14, 2010.
3. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-432.
4. Leichman CG, Leichman L, Spears CP et al. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993;85: 41-44.
5. Hansen RM. 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 1991;9:637-642.
6. Mori A, Bertoglio S, Guglielmi A et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993;33: 179-180.
7. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
8. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.
9. Cassidy J, Clarke S, Díaz-Rubio E et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105:58-64.
10. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
11. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-5917.
12. Scheithauer W, Kornek GV, Raderer M et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: A phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002;13:1583-1589.
13. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523-3529.
14. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-1312.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Benson AB 3rd, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
17. Traina TA, Theodoulou M, Dugan U et al. A novel capecitabine dosing schedule combined with bevacizumab is safe and effective in patients with metastatic breast cancer. Cancer Res 2009;69(suppl):395S.
18. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118-2123.